Related Experiment Video
Updated: Jul 15, 2026
09:25
In vitro Reconstitution of the Active T. castaneum Telomerase
Published on: July 14, 2011
Monoclonal antibodies against human telomerase reverse transcriptase (hTERT): preparation, characterization, and
1Department of Pathology, The Health Science Center of Peking University, Beijing 100083, China.
Hybridoma
|October 18, 2001
Summary
Researchers developed specific monoclonal antibodies targeting the human telomerase reverse transcriptase (hTERT) catalytic subunit. These novel antibodies can detect native hTERT in cancer cells and tissues, aiding cancer research.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- The catalytic subunit of human telomerase reverse transcriptase (hTERT) is crucial for telomerase activation in cancer.
- Targeting hTERT is a potential strategy for cancer therapy and diagnostics.
Purpose of the Study:
- To develop and characterize monoclonal antibodies (MAbs) specifically against the hTERT protein.
- To assess the utility of these MAbs in detecting native hTERT in cancer contexts.
Main Methods:
- Synthesis of an hTERT-derived peptide (hTERT(9)) for immunization.
- Generation of hybridomas through splenocyte fusion and screening for anti-hTERT(9) antibody production.
- Characterization of MAbs using Western blot and immunohistochemistry on human cancer cells and tissues.
Main Results:
- Three stable hybridoma clones producing anti-hTERT(9) MAbs were successfully generated.
- The developed MAbs demonstrated specificity for hTERT(9) and reactivity with native hTERT.
- Antibody binding was confirmed in Western blot and immunohistochemistry analyses of cancer samples.
Conclusions:
- Monoclonal antibodies against the hTERT(9) peptide recognize native hTERT.
- These MAbs hold potential as valuable tools for cancer research and diagnostics.
More Related Videos
Related Concept Videos
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...